CCL2 and neoplasm: The neutralization of IL-17 resulted in the no effect of BMMCs on Treg cell infiltration (Fig. 4A), Since MDSCs was the cellular source of IL-17 in this tumor model, we therefore depleted MDSCs by i.p. injection of anti-Gr-1 depleting antibody [31] or i.p. injected anti-CCL2 neutralizing antibody to inhibit MDSC migration to tumor [27].